Hana Pharm Co Ltd (293480.KS) stock: key figures, P/E, revenue and dividend

Health Care · Pharmaceuticals · South Korea · ISIN KR7293480000

Price
8,080.00 KRW
Market cap
143.20 bn KRW
P/E (2025)
16.31
P/S (2025)
0.60
Dividend yield
3.22 %
Net margin
3.67 %
Return on equity (ROE)
2.80 %
Return on assets (ROA)
2.10 %

Hana Pharm Co Ltd financials

Fiscal year20242025
Revenue225.34 bn KRW239.50 bn KRW
Gross profit141.29 bn KRW144.86 bn KRW
Operating income25.15 bn KRW25.82 bn KRW
EBIT25.15 bn KRW25.82 bn KRW
Net income21.25 bn KRW8.78 bn KRW
Diluted EPS – continuing operations1,228.36 KRW495.29 KRW

Full history since 2016, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

Sign up for freeOpen interactive view

About Hana Pharm Co Ltd

Hana Pharm Co., Ltd. develops and provides various pharmaceutical products in South Korea and internationally. It offers anesthetics, narcotic analgesics, antiemetics, muscle relaxants, cardiovascular and endocrine system, gastrointestinal system, respiratory system, antibiotics, dermatology, urinology, osteoporosis, and central nervous system products, as well as analgesics, antipyretics, and anti-inflammatory drugs. The company was founded in 1996 and is headquartered in Seoul, South Korea.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 30.10.2026. Details in the risk notice.